Publications
Integrating AI/ML Models for Patient Stratification Leveraging Omics Dataset and Clinical Biomarkers from COVID-19 Patients
In this manuscript, we demonstrate the recent advances and predictive accuracies in AI- and ML-based patient stratification modeling linking omics and clinical biomarker datasets, focusing on COVID-19 patients.
Integrating AI/ML Models for Patient Stratification Leveraging Omics Dataset and Clinical Biomarkers from COVID-19 Patients
In this manuscript, we demonstrate the recent advances and predictive accuracies in AI- and ML-based patient stratification modeling linking omics and clinical biomarker datasets, focusing on COVID-19 patients.
Pathways for Successful AI Adoption in Drug Development
Specific benchmarking practices, the use of Explainable AI and a well-developed technology roadmap are critical success factors to effectively onboard AI/ML for drug development.
Pathways for Successful AI Adoption in Drug Development
Specific benchmarking practices, the use of Explainable AI and a well-developed technology roadmap are critical success factors to effectively onboard AI/ML for drug development.
How Taking Smart Risks Makes Drug Development Less Speculative
Originally published by Forbes Technology Council. It’s impossible to totally eliminate risk in drug discovery. However, AI-driven approaches and other breakthrough technologies are continually proving their worth, helping create tangible efficiencies and better outcomes for drugmakers.
How Taking Smart Risks Makes Drug Development Less Speculative
Originally published by Forbes Technology Council. It’s impossible to totally eliminate risk in drug discovery. However, AI-driven approaches and other breakthrough technologies are continually proving their worth, helping create tangible efficiencies and better outcomes for drugmakers.
In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome
Originally published in Pharmaceutical Research Purpose Dysregulations of key signaling pathways in metabolic syndrome are multifactorial, eventually leading to cardiovascular events. Hyperglycemia in conjunction with dyslipidemia induces insulin resistance and provokes release of proinflammatory cytokines resulting in chronic inflammation, accelerated…
In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome
Originally published in Pharmaceutical Research Purpose Dysregulations of key signaling pathways in metabolic syndrome are multifactorial, eventually leading to cardiovascular events. Hyperglycemia in conjunction with dyslipidemia induces insulin resistance and provokes release of proinflammatory cytokines resulting in chronic inflammation, accelerated…
.svg)
